BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Diffuse Large B-Cell Lymphoma readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Diffuse Large B-Cell 
 Lymphoma\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06287398-10986@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06287398)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASC
 T & Epcor Consolidation in Patients With Relapsed LBCL\nEstimated primary 
 completion: November 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/epcoritamab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06287398
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04442022-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rituxan (Rituximab): Phase 2/3 readout est. (NCT04442022)
DESCRIPTION:Rituxan (Rituximab)\, phase 2/3\, Diffuse Large B-Cell Lymphoma
 .\nStudy: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) 
 With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Lar
 ge B-cell Lymphoma\nEstimated primary completion: December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04442022
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03758989-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT03758989)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Study of PET Adapted Therapy and Non-invasive Monitoring for Pre
 viously Untreated Limited Stage Diffuse Large B Cell Lymphoma\nEstimated p
 rimary completion: 1 December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT03758989
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05563844-3154@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Purinostat Mesylate: Phase 2 readout est. (NCT05563844)
DESCRIPTION:Purinostat Mesylate\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Study of Purinostat Mesylate for Injection in the Treatment of Rel
 apsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)\nEstimated p
 rimary completion: 30 December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/purinostat-mesylate#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05563844
URL:https://assetmemo.bio/drug/purinostat-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06570447-2286@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Chidamide: Phase 2 readout est. (NCT06570447)
DESCRIPTION:Chidamide\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: Gl
 ofitamab Combination With Chidamide in Patients With Recurrent/Refractory 
 DLBCL\nEstimated primary completion: 31 December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06570447
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01804686-2041@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ibrutinib: Phase 3 readout est. (NCT01804686)
DESCRIPTION:Ibrutinib\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: A 
 Long-term Extension Study of PCI-32765 (Ibrutinib)\nEstimated primary comp
 letion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/ibrutinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT01804686
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04978584-3339@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270116
DTEND;VALUE=DATE:20270117
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04978584)
DESCRIPTION:Acalabrutinib\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Rituximab\, Lenalidomide\, Acalabrutinib\, Tafasitamab Alone and With Co
 mbination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal C
 enter Diffuse Large B-Cell Lymphoma\, Smart Stop Study\nEstimated primary 
 completion: 16 January 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/acalabrutinib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT04978584
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04978584-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270116
DTEND;VALUE=DATE:20270117
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT04978584)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Rituximab\, Lenalidomide\, Acalabrutinib\, Tafasitamab Alone and W
 ith Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germ
 inal Center Diffuse Large B-Cell Lymphoma\, Smart Stop Study\nEstimated pr
 imary completion: 16 January 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT04978584
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04978584-5647@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270116
DTEND;VALUE=DATE:20270117
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT04978584)
DESCRIPTION:Tafasitamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Rituximab\, Lenalidomide\, Acalabrutinib\, Tafasitamab Alone and With Comb
 ination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Cen
 ter Diffuse Large B-Cell Lymphoma\, Smart Stop Study\nEstimated primary co
 mpletion: 16 January 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/tafasitamab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT04978584
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05256641-3339@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Acalabrutinib: Phase 1/2 readout est. (NCT05256641)
DESCRIPTION:Acalabrutinib\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStu
 dy: Acalabrutinib Maintenance for the Treatment of Patients With Large B-c
 ell Lymphoma\nEstimated primary completion: 31 January 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05256641
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04529772-3339@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270222
DTEND;VALUE=DATE:20270223
SUMMARY:Acalabrutinib: Phase 3 readout est. (NCT04529772)
DESCRIPTION:Acalabrutinib\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy
 : A Combination of Acalabrutinib With R-CHOP in Subjects With Previously U
 ntreated Non-GCB DLBCL (ACE-LY-312)\nEstimated primary completion: 22 Febr
 uary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/acalabruti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04529772
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05451810-10986@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT05451810)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Admini
 stered in the Outpatient Setting in Adult Participants With Relapsed or Re
 fractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma\nEs
 timated primary completion: March 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05451810
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06929624-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06929624)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus
  R-GemOx in Diffuse Large B-cell Lymphoma\nEstimated primary completion: M
 arch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0692
 9624
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06929624-11073@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:SHR-A1912: Phase 3 readout est. (NCT06929624)
DESCRIPTION:SHR-A1912\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: A 
 Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx i
 n Diffuse Large B-cell Lymphoma\nEstimated primary completion: March 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/shr-a1912#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06929624
URL:https://assetmemo.bio/drug/shr-a1912#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04799275-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Rituxan (Rituximab): Phase 2/3 readout est. (NCT04799275)
DESCRIPTION:Rituxan (Rituximab)\, phase 2/3\, Diffuse Large B-Cell Lymphoma
 .\nStudy: Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy
  in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell L
 ymphoma\nEstimated primary completion: 1 March 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04799275
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07489989-2286@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:Chidamide: Phase 2 readout est. (NCT07489989)
DESCRIPTION:Chidamide\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: En
 hancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and P
 D-1 Inhibitor Combination.\nEstimated primary completion: 15 May 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07489989
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07552324-2286@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Chidamide: Phase 2 readout est. (NCT07552324)
DESCRIPTION:Chidamide\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: St
 udy on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisafto
 clax in Combination With Pola-R-CHP\nEstimated primary completion: 31 May 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07552324
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05578976-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT05578976)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Study to Evaluate Change in Disease Activity of Subcutaneous (SC
 ) Epcoritamab Combined With Intravenous and Oral Rituximab\, Cyclophospham
 ide\, Doxorubicin Hydrochloride\, Vincristine\, and Prednisone (R-CHOP) or
  R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Ly
 mphoma (DLBCL)\nEstimated primary completion: June 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05578976
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05578976-10986@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Epcoritamab: Phase 3 readout est. (NCT05578976)
DESCRIPTION:Epcoritamab\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcori
 tamab Combined With Intravenous and Oral Rituximab\, Cyclophosphamide\, Do
 xorubicin Hydrochloride\, Vincristine\, and Prednisone (R-CHOP) or R-CHOP 
 in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (
 DLBCL)\nEstimated primary completion: June 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05578976
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06834373-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270610
DTEND;VALUE=DATE:20270611
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06834373)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refr
 actory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy\nE
 stimated primary completion: 10 June 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06834373
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03960840-2041@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ibrutinib: Phase 1/2 readout est. (NCT03960840)
DESCRIPTION:Ibrutinib\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Phase I/II Study of Rapcabtagene Autoleucel in CLL\, 3L+ DLBCL\, r/r ALL a
 nd 1L HR LBCL\nEstimated primary completion: 30 June 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ibrutinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT03960840
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07159906-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT07159906)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Diffuse Large B-Cell Lymphoma
 .\nStudy: Homoharringtonine\, BCL-2 Inhibitor\, Rituximab\, and Prednisone
  in Relapsed/Refractory Diffuse Large B-Cell Lymphoma\nEstimated primary c
 ompletion: 1 August 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07159906
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03223610-2041@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270812
DTEND;VALUE=DATE:20270813
SUMMARY:Ibrutinib: Phase 1/2 readout est. (NCT03223610)
DESCRIPTION:Ibrutinib\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Venetoclax\, Ibrutinib\, Prednisone\, Obinutuzumab\, and Revlimid (ViPOR) 
 in Relapsed/Refractory B-cell Lymphoma\nEstimated primary completion: 12 A
 ugust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibrutinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT032
 23610
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06891157-2286@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270820
DTEND;VALUE=DATE:20270821
SUMMARY:Chidamide: Phase 2 readout est. (NCT06891157)
DESCRIPTION:Chidamide\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: Ch
 idamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Ce
 ll Lymphoma With Other Molecular Subtypes\nEstimated primary completion: 2
 0 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/chidam
 ide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06891157
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06536049-2041@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Ibrutinib: Phase 1/2 readout est. (NCT06536049)
DESCRIPTION:Ibrutinib\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Agg
 ressive B-Cell Non-Hodgkin Lymphoma\nEstimated primary completion: 31 Augu
 st 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibrutinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT065360
 49
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06536049-10986@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT06536049)
DESCRIPTION:Epcoritamab\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory A
 ggressive B-Cell Non-Hodgkin Lymphoma\nEstimated primary completion: 31 Au
 gust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritama
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 536049
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04542824-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT04542824)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Diffuse Large B-Cell Lymphoma
 .\nStudy: Trial of the Safety and Efficacy of Epcoritamab in Japanese Subj
 ects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-
 NHL)\nEstimated primary completion: September 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04542824
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04542824-10986@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT04542824)
DESCRIPTION:Epcoritamab\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects Wit
 h Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)\nEs
 timated primary completion: September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04542824
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07451652-10986@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07451652)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Low Dose Epcoritamab Plus GemOx in R/R DLBCL\nEstimated primary completion
 : September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/epc
 oritamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07451652
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05139017-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:Rituxan (Rituximab): Phase 2/3 readout est. (NCT05139017)
DESCRIPTION:Rituxan (Rituximab)\, phase 2/3\, Diffuse Large B-Cell Lymphoma
 .\nStudy: A Study of Zilovertamab Vedotin (MK-2140) in Combination With St
 andard of Care in Participants With Relapsed or Refractory Diffuse Large B
 -Cell Lymphoma (rrDLBCL) (MK-2140-003)\nEstimated primary completion: 24 S
 eptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituxi
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05139017
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05139017-9128@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:Zilovertamab vedotin: Phase 2/3 readout est. (NCT05139017)
DESCRIPTION:Zilovertamab vedotin\, phase 2/3\, Diffuse Large B-Cell Lymphom
 a.\nStudy: A Study of Zilovertamab Vedotin (MK-2140) in Combination With S
 tandard of Care in Participants With Relapsed or Refractory Diffuse Large 
 B-Cell Lymphoma (rrDLBCL) (MK-2140-003)\nEstimated primary completion: 24 
 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zilov
 ertamab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05139017
URL:https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04663347-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT04663347)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Diffuse Large B-Cell Lymphoma
 .\nStudy: Safety and Efficacy Trial of Epcoritamab Combinations in Subject
 s With B-cell Non-Hodgkin Lymphoma (B-NHL)\nEstimated primary completion: 
 30 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ri
 tuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04663347
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04663347-10986@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT04663347)
DESCRIPTION:Epcoritamab\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B
 -cell Non-Hodgkin Lymphoma (B-NHL)\nEstimated primary completion: 30 Septe
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritama
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 663347
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06458439-10986@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06458439)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab-CAR T Cells for Large B-cell Lymphomas\nEstimated primary comp
 letion: October 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /epcoritamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06458439
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04002947-3339@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20271012
DTEND;VALUE=DATE:20271013
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04002947)
DESCRIPTION:Acalabrutinib\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffus
 e Large B-cell Lymphoma\nEstimated primary completion: 12 October 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04002947
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04002947-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20271012
DTEND;VALUE=DATE:20271013
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT04002947)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated 
 Diffuse Large B-cell Lymphoma\nEstimated primary completion: 12 October 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04002947
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07124936-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20271026
DTEND;VALUE=DATE:20271027
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT07124936)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Diffuse Large B-Cell Lymphoma
 .\nStudy: A Study of HDM2005 in Combination With Standard of Care in Patie
 nts With Diffuse Large B-Cell Lymphoma\nEstimated primary completion: 26 O
 ctober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituxima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 124936
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04546620-3339@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04546620)
DESCRIPTION:Acalabrutinib\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffus
 e Large B-cell Lymphoma (DLBCL)\nEstimated primary completion: November 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0454662
 0
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07001540-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20271115
DTEND;VALUE=DATE:20271116
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07001540)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combi
 ned With Rituximab\, Gemcitabine\, and Oxaliplatin (Pola-R-GemOx) as Salva
 ge Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) P
 atients Ineligible for Autologous Transplantation\nEstimated primary compl
 etion: 15 November 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07001540
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07269639-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT07269639)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Diffuse Large B-Cell Lymphoma
 .\nStudy: Golcadomide\, Poseltinib\, and Rituximab for Relapsed/Refractory
  Diffuse Large B-cell Lymphoma\nEstimated primary completion: 1 December 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07269639
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06890884-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20271213
DTEND;VALUE=DATE:20271214
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06890884)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab 
 Plus Cyclophosphamide\, Doxorubicin\, and Prednisone (R-CHP) Versus Polatu
 zumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLB
 CL) (MK-2140-011/waveLINE-011)\nEstimated primary completion: 13 December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06890884
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06890884-9128@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20271213
DTEND;VALUE=DATE:20271214
SUMMARY:Zilovertamab vedotin: Phase 2 readout est. (NCT06890884)
DESCRIPTION:Zilovertamab vedotin\, phase 2\, Diffuse Large B-Cell Lymphoma.
 \nStudy: A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab
  Plus Cyclophosphamide\, Doxorubicin\, and Prednisone (R-CHP) Versus Polat
 uzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DL
 BCL) (MK-2140-011/waveLINE-011)\nEstimated primary completion: 13 December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/zilovertamab-v
 edotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06890884
URL:https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07034508-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20271220
DTEND;VALUE=DATE:20271221
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07034508)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab
  Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1\nEstimated pri
 mary completion: 20 December 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07034508
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06742502-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06742502)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated 
 PMBL\nEstimated primary completion: 30 December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06742502
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06441097-3339@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT06441097)
DESCRIPTION:Acalabrutinib\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL\nEstimated prima
 ry completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/acalabrutinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06441097
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06441097-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06441097)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL\nEstimated
  primary completion: 31 December 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06441097
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06765317-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06765317)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Study of Glofitamab-based Treatment in People With Diffuse Large
  B-cell Lymphoma\nEstimated primary completion: January 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06765317
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06931652-10986@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06931652)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the C
 NS Treated With Lenalidomide and Rituximab\nEstimated primary completion: 
 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcorit
 amab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06931652
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06508658-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06508658)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidom
 ide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infus
 ed Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relap
 sed or Refractory Diffuse Large B-Cell Lymphoma\nEstimated primary complet
 ion: March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ritu
 ximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06508658
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06508658-10986@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Epcoritamab: Phase 3 readout est. (NCT06508658)
DESCRIPTION:Epcoritamab\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tabl
 ets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemci
 tabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or R
 efractory Diffuse Large B-Cell Lymphoma\nEstimated primary completion: Mar
 ch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0650
 8658
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05025800-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT05025800)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Diffuse Large B-Cell Lymphoma
 .\nStudy: ALX148\, Rituximab and Lenalidomide for the Treatment of Indolen
 t and Aggressive B-cell Non-Hodgkin Lymphoma\nEstimated primary completion
 : 21 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ritu
 ximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05025800
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06091865-5820@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Odronextamab: Phase 3 readout est. (NCT06091865)
DESCRIPTION:Odronextamab\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy:
  A Study to Compare How Well Odronextamab Combined With Chemotherapy Works
  and How Safe it is Against Rituximab Combined With Chemotherapy\, in Adul
 t Patients With Previously Untreated Diffuse Large B-cell Lymphoma\nEstima
 ted primary completion: 30 March 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/odronextamab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06091865
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06784726-5820@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20280410
DTEND;VALUE=DATE:20280411
SUMMARY:Odronextamab: Phase 2 readout est. (NCT06784726)
DESCRIPTION:Odronextamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy:
  Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CA
 R-T\nEstimated primary completion: 10 April 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/odronextamab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06784726
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06803693-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06803693)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
 \nEstimated primary completion: 30 April 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06803693
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07601607-2286@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20280530
DTEND;VALUE=DATE:20280531
SUMMARY:Chidamide: Phase 1/2 readout est. (NCT07601607)
DESCRIPTION:Chidamide\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse
  Large B-cell Lymphoma\nEstimated primary completion: 30 May 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07601607
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07601607-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20280530
DTEND;VALUE=DATE:20280531
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT07601607)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Diffuse Large B-Cell Lymphoma
 .\nStudy: Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refracto
 ry Diffuse Large B-cell Lymphoma\nEstimated primary completion: 30 May 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07601607
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07814001-10986@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07814001)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma
  After Second-Line CAR T-cell Therapy\nEstimated primary completion: July 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0781400
 1
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06905509-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06905509)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and 
 Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or 
 Refractory Large B-cell Lymphoma\nEstimated primary completion: 1 July 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06905509
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06905509-10986@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06905509)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologo
 us Hematopoietic Cell Transplant for the Treatment of Relapsed or Refracto
 ry Large B-cell Lymphoma\nEstimated primary completion: 1 July 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06905509
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07397832-2286@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:Chidamide: Phase 2 readout est. (NCT07397832)
DESCRIPTION:Chidamide\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: CR
 P Regimen in Treating Elderly Patients With Previously Untreated Double-Po
 sitive DLBCL\nEstimated primary completion: 30 July 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07397832
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07397832-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07397832)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: CRP Regimen in Treating Elderly Patients With Previously Untreated
  Double-Positive DLBCL\nEstimated primary completion: 30 July 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07397832
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06045247-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06045247)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CV
 P for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patient
 s With Newly Diagnosed Diffuse Large B-cell Lymphoma\nEstimated primary co
 mpletion: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06045247
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06045247-10986@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06045247)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Ol
 der Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With N
 ewly Diagnosed Diffuse Large B-cell Lymphoma\nEstimated primary completion
 : 31 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcor
 itamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06045247
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03984448-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20280813
DTEND;VALUE=DATE:20280814
SUMMARY:Rituxan (Rituximab): Phase 2/3 readout est. (NCT03984448)
DESCRIPTION:Rituxan (Rituximab)\, phase 2/3\, Diffuse Large B-Cell Lymphoma
 .\nStudy: Testing the Addition of a New Anti-cancer Drug\, Venetoclax\, to
  Usual Chemotherapy for High Grade B-cell Lymphomas\nEstimated primary com
 pletion: 13 August 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT03984448
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07588698-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07588698)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Epcoritamab in Combination With R-CHOP for Patients With Aggressiv
 e Non-Hodgkin Lymphoma\nEstimated primary completion: 31 August 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07588698
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07588698-10986@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07588698)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Ho
 dgkin Lymphoma\nEstimated primary completion: 31 August 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07588698
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06521255-5647@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Tafasitamab: Phase 3 readout est. (NCT06521255)
DESCRIPTION:Tafasitamab\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combin
 ation With Gemcitabine and Oxaliplatin Versus Rituximab in Combination Wit
 h Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse
  Large B-Cell Lymphoma\nEstimated primary completion: September 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tafasitamab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06521255
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06649812-2041@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT06649812)
DESCRIPTION:Ibrutinib\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: Te
 sting the Effectiveness of a Combination Targeted Therapy (ViPOR) for Pati
 ents With Relapsed and/or Refractory Aggressive B-cell Lymphoma\nEstimated
  primary completion: 1 September 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/ibrutinib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06649812
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07255963-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07255963)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Pirtobrutinib\, Lisaftoclax\, and Rituximab in the Treatment of R/
 R DLBCL\nEstimated primary completion: 30 September 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07255963
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06854159-5820@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Odronextamab: Phase 2 readout est. (NCT06854159)
DESCRIPTION:Odronextamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy:
  Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B
 -cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy\n
 Estimated primary completion: October 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/odronextamab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06854159
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06516978-2286@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Chidamide: Phase 2 readout est. (NCT06516978)
DESCRIPTION:Chidamide\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: A 
 Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and 
 Pola-RCHP in Previously Untreated Patients With DLBCL\nEstimated primary c
 ompletion: 1 October 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/chidamide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06516978
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06516978-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06516978)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RC
 HOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL\nEstimated
  primary completion: 1 October 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06516978
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07917624-2286@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Chidamide: Phase 2 readout est. (NCT07917624)
DESCRIPTION:Chidamide\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: Pr
 ophylactic Strategies for Mitigating Central Nervous System Relapse in Dif
 fuse Large B-Cell Lymphoma\nEstimated primary completion: 31 October 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07917624
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07818499-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rituxan (Rituximab): Phase 1/2 readout est. (NCT07818499)
DESCRIPTION:Rituxan (Rituximab)\, phase 1/2\, Diffuse Large B-Cell Lymphoma
 .\nStudy: A Study of BL-M08D1 in Combination With Immunochemotherapy in Pa
 tients With Diffuse Large B-Cell Lymphoma\nEstimated primary completion: D
 ecember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituxim
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7818499
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07938619-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07938619)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Tafasitamab\, Lenalidomide\, Rituximab\, and Orelabrutinib for Pat
 ients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma\nEstimated
  primary completion: 1 December 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07938619
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07938619-5647@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT07938619)
DESCRIPTION:Tafasitamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Tafasitamab\, Lenalidomide\, Rituximab\, and Orelabrutinib for Patients Wi
 th Relapsed or Refractory Diffuse Large B-Cell Lymphoma\nEstimated primary
  completion: 1 December 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tafasitamab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07938619
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06220032-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20281215
DTEND;VALUE=DATE:20281216
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06220032)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexra
 zoxane in Patients With Diffuse Large-B Cell Lymphoma\nEstimated primary c
 ompletion: 15 December 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06220032
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06925555-2202@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Brentuximab Vedotin: Phase 2 readout est. (NCT06925555)
DESCRIPTION:Brentuximab Vedotin\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DL
 BCL-NOS\nEstimated primary completion: 30 December 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06925555
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621406-5647@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT07621406)
DESCRIPTION:Tafasitamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Efficacy and Safety of Sequential Autologous Hematopoietic Stem Cell Trans
 plantation Combined With Tafasitamab\, Lenalidomide\, and Standard Immunoc
 hemotherapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma\nEstimat
 ed primary completion: 31 December 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/tafasitamab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07621406
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06792253-3395@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ifupinostat: Phase 3 readout est. (NCT06792253)
DESCRIPTION:Ifupinostat\, phase 3\, Relapsed/Refractory Diffuse Large B-Cel
 l Lymphoma.\nStudy: Study Comparing BEBT-908 Combined With R to SOC for th
 e Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma\nEstimate
 d primary completion: 31 December 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/ifupinostat#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06792253
URL:https://assetmemo.bio/drug/ifupinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06792253-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06792253)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Study Comparing BEBT-908 Combined With R to SOC for the Treatment 
 of Relapsed/Refractory Diffuse Large B-Cell Lymphoma\nEstimated primary co
 mpletion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06792253
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04604067-3339@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20290130
DTEND;VALUE=DATE:20290131
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04604067)
DESCRIPTION:Acalabrutinib\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Mult
 icenter\, Open-label\, Phase II Trial.\nEstimated primary completion: 30 J
 anuary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/acalabru
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04604067
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05820841-3339@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Acalabrutinib: Phase 3 readout est. (NCT05820841)
DESCRIPTION:Acalabrutinib\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untrea
 ted Diffuse Large B-Cell Lymphoma\nEstimated primary completion: February 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05820
 841
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06395103-9128@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Zilovertamab vedotin: Phase 1/2 readout est. (NCT06395103)
DESCRIPTION:Zilovertamab vedotin\, phase 1/2\, Diffuse Large B-Cell Lymphom
 a.\nStudy: Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult
  Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/L
 IGHTBEAM-U01)\nEstimated primary completion: 31 March 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06395103
URL:https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05952024-3339@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20290422
DTEND;VALUE=DATE:20290423
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT05952024)
DESCRIPTION:Acalabrutinib\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail P
 atients With DLBCL\nEstimated primary completion: 22 April 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05952024
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05952024-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20290422
DTEND;VALUE=DATE:20290423
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT05952024)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Study of Acalabrutinib and Rituximab in Untreated Elderly and/or F
 rail Patients With DLBCL\nEstimated primary completion: 22 April 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05952024
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05406401-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20290426
DTEND;VALUE=DATE:20290427
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT05406401)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cycl
 ophosphamide\, Doxorubicin\, and Prednisone Plus Rituximab or Rituximab Bi
 osimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymph
 oma (DLBCL) (MK-2140-007)\nEstimated primary completion: 26 April 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/rituximab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05406401
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05406401-9128@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20290426
DTEND;VALUE=DATE:20290427
SUMMARY:Zilovertamab vedotin: Phase 2 readout est. (NCT05406401)
DESCRIPTION:Zilovertamab vedotin\, phase 2\, Diffuse Large B-Cell Lymphoma.
 \nStudy: A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyc
 lophosphamide\, Doxorubicin\, and Prednisone Plus Rituximab or Rituximab B
 iosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymp
 homa (DLBCL) (MK-2140-007)\nEstimated primary completion: 26 April 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/zilovertamab-vedotin#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05406
 401
URL:https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07507318-2286@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Chidamide: Phase 2 readout est. (NCT07507318)
DESCRIPTION:Chidamide\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: Ch
 idamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Compl
 ete Remission\nEstimated primary completion: 30 June 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07507318
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011056-3154@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Purinostat Mesylate: Phase 3 readout est. (NCT07011056)
DESCRIPTION:Purinostat Mesylate\, phase 3\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Phase III Clinical Study of Purinostat Mesylate for Injection in
  Patients With Diffuse Large B-cell Lymphoma\nEstimated primary completion
 : 30 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/purin
 ostat-mesylate#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07011056
URL:https://assetmemo.bio/drug/purinostat-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06717347-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20290702
DTEND;VALUE=DATE:20290703
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT06717347)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Diffuse Large B-Cell Lymphoma.\
 nStudy: A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination Wit
 h Rituximab Plus Cyclophosphamide\, Doxorubicin\, and Prednisone (R-CHP) V
 ersus Rituximab Plus Cyclophosphamide\, Doxorubicin\, Vincristine\, and Pr
 ednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140
 -010)\nEstimated primary completion: 2 July 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/rituximab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06717347
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06717347-9128@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20290702
DTEND;VALUE=DATE:20290703
SUMMARY:Zilovertamab vedotin: Phase 3 readout est. (NCT06717347)
DESCRIPTION:Zilovertamab vedotin\, phase 3\, Diffuse Large B-Cell Lymphoma.
 \nStudy: A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination Wi
 th Rituximab Plus Cyclophosphamide\, Doxorubicin\, and Prednisone (R-CHP) 
 Versus Rituximab Plus Cyclophosphamide\, Doxorubicin\, Vincristine\, and P
 rednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-214
 0-010)\nEstimated primary completion: 2 July 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06717347
URL:https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07493109-2286@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Chidamide: Phase 3 readout est. (NCT07493109)
DESCRIPTION:Chidamide\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: Ch
 idamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patient
 s Initially Treated With R-CHOP\nEstimated primary completion: 30 Septembe
 r 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/chidamide#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0749310
 9
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07365306-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20291015
DTEND;VALUE=DATE:20291016
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07365306)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Epcoritamab\, Rituximab\, Gemcitabine and Oxaliplatin (R-GemOx) as
  Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment 
 of Relapsed/Refractory Diffuse Large B-Cell Lymphoma\nEstimated primary co
 mpletion: 15 October 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07365306
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07365306-10986@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20291015
DTEND;VALUE=DATE:20291016
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07365306)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab\, Rituximab\, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage
  Therapy Before Autologous Stem Cell Transplant for the Treatment of Relap
 sed/Refractory Diffuse Large B-Cell Lymphoma\nEstimated primary completion
 : 15 October 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ep
 coritamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07365306
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887750-5820@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Odronextamab: Phase 1/2 readout est. (NCT07887750)
DESCRIPTION:Odronextamab\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStud
 y: REGN9220 in Combination With Odronextamab in Adult Participants With Re
 lapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)\nEst
 imated primary completion: 1 November 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/odronextamab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07887750
URL:https://assetmemo.bio/drug/odronextamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06664411-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06664411)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Pola-ZR2P in Previously Untreated DLBCL\nEstimated primary complet
 ion: December 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/r
 ituximab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06664411
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05890352-5647@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT05890352)
DESCRIPTION:Tafasitamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Retur
 ned or Did Not Respond to Treatment\nEstimated primary completion: 1 Decem
 ber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tafasitamab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT058
 90352
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07493148-2286@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Chidamide: Phase 2 readout est. (NCT07493148)
DESCRIPTION:Chidamide\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: Ch
 idamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenanc
 e in Elderly Newly Diagnosed MYC/BCL2+ DLBCL\nEstimated primary completion
 : 30 December 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 hidamide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07493148
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07493148-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07493148)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 
 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL\nEstimated primary 
 completion: 30 December 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07493148
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06890585-2286@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Chidamide: Phase 2 readout est. (NCT06890585)
DESCRIPTION:Chidamide\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: Za
 nubrutinib\, Chidamide\, and Rituximab Induction With or Without CHOP Vers
 us R-CHOP in Newly Diagnosed Double-Expressor DLBCL\nEstimated primary com
 pletion: 31 December 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/chidamide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06890585
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06890585-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT06890585)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Zanubrutinib\, Chidamide\, and Rituximab Induction With or Without
  CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL\nEstimated p
 rimary completion: 31 December 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06890585
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06238648-10986@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06238648)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients 
 Not in Complete Remission After CD19-directed CAR-T Therapy\nEstimated pri
 mary completion: 31 December 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/epcoritamab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06238648
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07502872-5647@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Tafasitamab: Phase 2 readout est. (NCT07502872)
DESCRIPTION:Tafasitamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 TPG: Tafasitamab\, Polatuzumab Vedotin\, and Glofitamab as First-line Ther
 apy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma\nEsti
 mated primary completion: 1 January 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tafasitamab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07502872
URL:https://assetmemo.bio/drug/tafasitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07197307-10986@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07197307)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Di
 ffuse Large B-cell Lymphoma (DLBCL)\nEstimated primary completion: 30 Apri
 l 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07197
 307
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07097363-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT07097363)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Epcoritamab With Dose Adjusted Etoposide\, Cyclophosphamide\, Vinc
 ristine\, Doxorubicin\, Prednisone and Rituximab (EPOCH-R) for the Treatme
 nt of Aggressive B-Cell Non-Hodgkin Lymphoma\nEstimated primary completion
 : 31 May 2030. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rituxi
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07097363
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07097363-10986@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT07097363)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab With Dose Adjusted Etoposide\, Cyclophosphamide\, Vincristine\
 , Doxorubicin\, Prednisone and Rituximab (EPOCH-R) for the Treatment of Ag
 gressive B-Cell Non-Hodgkin Lymphoma\nEstimated primary completion: 31 May
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070973
 63
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06919939-10986@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20310107
DTEND;VALUE=DATE:20310108
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT06919939)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refract
 ory Large B-cell Lymphoma\nEstimated primary completion: 7 January 2031. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06919939
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03418038-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20310222
DTEND;VALUE=DATE:20310223
SUMMARY:Rituxan (Rituximab): Phase 2 readout est. (NCT03418038)
DESCRIPTION:Rituxan (Rituximab)\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Re
 fractory Lymphoma\, CCUS\, and Chronic Myelomonocytic Leukemia\nEstimated 
 primary completion: 22 February 2031. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/rituximab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03418038
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220187-4915@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20351001
DTEND;VALUE=DATE:20351002
SUMMARY:Rituxan (Rituximab): Phase 3 readout est. (NCT07220187)
DESCRIPTION:Rituxan (Rituximab)\, phase 3\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Adding Pirtobrutinib to the Usual Treatment for People With Newly 
 Diagnosed Richter Transformation\, The PIRAMID Trial\nEstimated primary co
 mpletion: 1 October 2035. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/rituximab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07220187
URL:https://assetmemo.bio/drug/rituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07917754-9128@assetmemo.bio
DTSTAMP:20261121T004517Z
DTSTART;VALUE=DATE:20370313
DTEND;VALUE=DATE:20370314
SUMMARY:Zilovertamab vedotin: Phase 2/3 readout est. (NCT07917754)
DESCRIPTION:Zilovertamab vedotin\, phase 2/3\, Diffuse Large B-Cell Lymphom
 a.\nStudy: A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Partic
 ipants With Diffuse Large B-cell Lymphoma (MK-1045-010)\nEstimated primary
  completion: 13 March 2037. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/zilovertamab-vedotin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07917754
URL:https://assetmemo.bio/drug/zilovertamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
